Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib
Pharmaceutical Science Advances · 2026-12 · 4 · 100125
DOI: 10.1016/j.pscia.2026.100125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Fuxun Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji'nan, Sh…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Opaganib is a proprietary, host-directed, potentially broadly potent, first-in-class oral sphingosine kinase 2 (SphK2) selective inhibitor developed by RedHill Biopharma Tel Aviv, Israel. It is currently the most widely used selective SphK2 inhibitor. It simultaneously inhibits three sphingolipid-metabolizing enzymes in human cells-SphK2, dihydroceramide desaturase (DES1), and glucosylceramide synthase (GCS)-leading to depletion of sphingosine 1-phosphate (S1P), accumulation of ceramides and dihydroceramides, and suppression of key pro-survival pathways including pERK, pAKT, and NF-κB. These events promote autophagy, apoptosis, and disruption of viral replication. A large body of evidence indicates that SphK plays an important role in health and disease. This study reviews the role and mechanisms of opaganib effects as anticancer, anti-inflammatory, and antiviral agent. The latest research directions for opaganib are described as gastrointestinal acute radiation syndrome (GI-ARS), chemical exposure indications, and COVID-19, Ebola, and other viruses, providing new therapeutic ideas and considerations for future research and clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji'nan, Shandong, 250117, PR China.
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong Province, 250012, PR China.
Förderung
- Ministry of Education
- Shandong Province Natural Science Foundation
Zitieren
APA
Huang, F., Zhan, P., Shi, X., Sun, Y., Song, X., Sun, P., & Liu, B. (2026). Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib. Pharmaceutical Science Advances, 4, 100125. https://doi.org/10.1016/j.pscia.2026.100125
Vancouver
Huang F, Zhan P, Shi X, Sun Y, Song X, Sun P, et al. Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib. Pharmaceutical Science Advances. 2026;4:100125. doi:10.1016/j.pscia.2026.100125
BibTeX
@article{Huang2026,
author = {Huang, Fuxun and Zhan, Peng and Shi, Xiujuan and Sun, Yueyang and Song, Xingbo and Sun, Peilu and Liu, Bo},
title = {Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib},
journal = {Pharmaceutical Science Advances},
year = {2026},
volume = {4},
pages = {100125},
doi = {10.1016/j.pscia.2026.100125}
}
EUVIMED